A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Active, not recruiting · Phase 3 · NCT03539744
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $16,807
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 265
About the trial
- Sponsor
- AbbVie (with Roche-Genentech)
- Tested
- Pomalidomide (drug), Dexamethasone (drug), Venetoclax (drug)
- Dates
- Started 2018-10-22; completion 2027-11
- Results posted
- Not yet
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
From ClinicalTrials.gov, last updated 2025-06-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $16,807 in research payments for this study in 2025 (5 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Chakra P. Chaulagain, MD Hematology & Oncology · Weston, FL
- Mehmet Kocoglu, MD Hematology & Oncology · Baltimore, MD
- Prashant Kapoor, MD Hematology · Rochester, MN
- Jason Valent, M.D. Hematology & Oncology · Strongsville, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Maryland Baltimore $8,745
- Mayo Clinic $3,392
- Cleveland Clinic of Florida $3,300
- Cleveland Clinic, OH $1,370
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.